Rezultati pretraživanja
  1. 1. velj

    1/ Let's differentiate pyogenic from amebic liver abscess in a today. We will examine DDx, risk factors, microbiology, clinical features, diagnostics, and treatment. This came from my most recent morning report.

    Prikaži ovu nit
  2. prije 23 sata

    New meta-analysis shows that hemodynamic response to beta-blockers in patients with cirrhosis + varices decrease the risk of: 🩸Bleeding 🌊Ascites 💤Encephalophaty 🦠Peritonitis ☠️Death ✅Both in patients with and without previous ascites

  3. prije 4 sata

    Check out the new Clinical Practice Update on Screening & Surveillance for Hepatocellular Carcinoma in Patients w/Nonalcoholic Fatty Liver Disease by et al Below are some of my take away points!

    Prikaži ovu nit
  4. prije 20 sati

    Meta analysis of 15 studies of primary or secondary prophylaxis of VH Responders: HVPG ⬇️ >20% from baseline or <12 mm Hg Responders with +/- ascites ➡️ Reduced risk of events/death/LT Reassess and resume that NSBB you held during admission!

  5. prije 3 sata

    Important PSA . Iron supplementation is essential in PHG and GAVE but more iron does not equal more absorbion

  6. prije 23 sata

    Who performs HVPG (hepatic venous pressure gradient) procedure in your patients with cirrhosis at your institution?

  7. Odgovor korisniku/ci

    I think most of us in are checking TMPT before AZA initiation. The real heterogeneity is in use of metabolites. Many not using, many using in narrow/specific cases.

  8. 2. velj

    One of the biggest differences between and is the practice of TPMT screening before starting AZA, and checking metabolites thereafter. Same drug, totally opposite approach. Who’s right and how do we reach a middle ground?

    Prikaži ovu nit
  9. 2. velj

    Everything u need to know about 💩, and liver disease in general by Professor Poop himself, THE Open access:

  10. 2. velj

    ➡️ lively debates and updates on most current research We are growing. Join us!

  11. 2. velj
  12. 1. velj

    From : "Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review"

  13. 1. velj
    Odgovor korisnicima

    I am not worthy! this is an important and super complicated topic. Would love to hear more about it and the motivation behind this great review from / /

  14. 31. sij

    Lucky I don’t have 10K followers but I am already on my way to be the Kardashian of 😀

  15. 31. sij

    Informe de posicionamiento terapéutico de en 1ª línea de tratamiento del hepatocarcinoma de . Las conclusiones no tienen desperdicio. Mientras, seguimos sin tratamientos de 2º línea a pesar de IPTs favorables 🤷‍♂️

  16. 31. sij

    Redefining cirrhotic cardiomyopathy 🤔 in . I definitely need a on this issue ... Is there anyone in ? maybe? 😇

  17. 31. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    We have done a couple of SLK in the last few years with good outcomes so far. I will explain our approach when I hear a few more answers from our colleagues.

  18. 30. sij

    I love these case-based discussions and learn so much. How often am I lucky enough to discuss complicated AIH cases with and so many other incredible hepatologists. Keep up the strong work !

  19. 30. sij

    How do you pronounce encephalopathy?

    Prikaži ovu nit
  20. 30. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    We don't. The last time I checked it, the cost of the technique was too high. We rely on ALT and IgG values ... Could you tell us something more about how did it help you with those patients?

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.